Aberrant stress response associated with severe hypoglycemia in a transgenic mouse model of Alzheimer's disease

Journal of Molecular Neuroscience

Volumn 13, Issue 1-2, 1999, Pages 159-165

  Pedersen, Ward A ^a   Culmsee, Carsten ^a   Ziegler, Dana ^a   Herman, James P ^a   Mattson, Mark P ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Amyloid; Corticosterone; Glucocorticoids; Hypothalamus; Pituitary; Transgenic

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CORTICOSTERONE; GLUCOCORTICOID; GLUCOSE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPOGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILIZATION STRESS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; STRESS; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 0033400774     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/jmn:13:1-2:159     Document Type: Article

References (24)

1. Ando Y., Brannstrom T., Uchida K., Nyhlin N., Nasman B., Suhr O., et al. (1998) Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J. Neurol. Sci. 156, 172-176.
2. Bruce-Keller A. J., Umberger G., McFall R., and Mattson M. P. (1999) Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann. Neurol. 45, 8-15.
3. Chapman P. F., White G. L., Jones M. W., Cooper-Blacketer D., Marshall V. J., Irizarry M., et al. (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271-276.
4. Cheng B. and Mattson M. P. (1992) Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: Prevention by NGF and bFGF. Exp. Neurol. 117, 114-123.
5. Duan W. and Mattson M. P. (1999) Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 57, 185-206.
6. Gros L., Virsolvy A., Salazar G., Bataille D., and Blache P. (1999) Characterization of low-affinity binding sites for glibenclamide on the Kir6.2 subunit of the β-cell KATP channel. Biochem. Biophys. Res. Commun. 257, 766-770.
7. Hatzinger M., Z'Brun A., Hemmeter U., Seifritz E., Baumann F., Holsboer-Trachsler E., et al. (1995) Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol. Aging 16, 205-209.
8. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
9. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., et al. (1998) Diffusible, nonfibrillar ligands derived from Abetal-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453.
10. Leakey J. E., Chen S., Manjgaladze M., Turturro A., Duffy P. H., Pipkin J. L., et al. (1994) Role of glucocorticoids and "caloric stress" in modulating the effects of caloric restriction in rodents. Ann. NY Acad. Sci. 719, 171-194.
11. Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R. E. (1992) β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376-389.
12. Nasman B., Olsson T., Fagerlund M., Eriksson S., Viitanen M., and Carlstrom K. (1996) Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer's disease. Biol. Psychiatry 39, 311-318.
13. O'Brien J. T., Schweitzer I., Ames D., Mastwyk M., and Colman P. (1994) The function of the hypothalamic-pituitary-adrenal axis in Alzheimer's disease. Response to insulin hypoglycaemia. Br. J. Psychiatry 165, 650-657.
14. O'Brien J. T., Ames D., Schweitzer I., Mastwyk M., and Colman P. (1996) Enhanced adrenal sensitivity to adrenocorticotrophic hormone (ACTH) is evidence of HPA axis hyperactivity in Alzheimer's disease. Psychol. Med. 26, 7-14.
15. Pedersen W. A., Fu W., Keller J. N., Markesberry W. R., Appel S., Smith R. G., et al. (1998) Protein modification by the lipid peroxidation product 4-Hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann. Neurol. 44, 819-824.
16. Raber J. (1998) Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits. Mol. Neurobiol. 18, 1-22.
17. Reisberg B., Borenstein J., Salob S. P., Ferris S. H., Franssen E., and Georgotas A. (1987) Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J. Clin. Psychiatry 48, Suppl., 9-15.
18. Sayre L. M., Zelasko D. A., Harris P. L., Perry G., Salomon R. G., and Smith M. A. J. (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. Neurochemistry 68, 2092-2097.
19. Smith-Swintosky V. L., Pettigrew L. C., Sapolsky R. M., Phares C., Craddock S. D., Brooke S. M., et al. (1996) Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures. J. Cereb. Blood Flow Metab. 16, 585-598.
20. Stein-Behrens B. A. and Sapolsky R. M. (1992) Stress, glucocorticoids, and aging. Aging Clin. Exp. Res. 4, 197-210.
21. Stewart J., Meaney M. J., Aitken D., Jensen L., and Kalant N. (1988) The effects of acute and life-long food restriction on basal and stress-induced serum corticosterone levels in young and aged rats. Endocrinology 123, 1934-1941.
22. Stopa E. G., Volicer L., Kuo-Leblanc V., Harper D., Lathi D., Tate B., et al. (1999) Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol. Exp. Neurol. 58, 29-39.
23. van de Nes J. A., Kamphorst W., Ravid R., and Swaab D. F. (1998) Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol. 96, 129-138.
24. Weiner M. F., Vobach S., Olsson K., Svetlik D., and Risser R. C. (1997) Cortisol secretion and Alzheimer's disease progression. Biol. Psychiatry 42, 1030-1038.